Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:ARZNYSE:ATCCVE:SCANASDAQ:SGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARZAralez PharmaceuticalsC$0.00C$0.29▼C$3.72C$28.89MN/A79,103 shs274,400 shsATCAtotech$22.71$21.22$18.06▼$25.94$4.42B0.631.09 million shsN/ASCASavary GoldC$0.12-4.2%C$0.12C$0.04▼C$0.13C$29.40MN/A830,838 shs204,500 shsSGISilicon Graphics International$60.50+0.8%$2.90$4.33▼$7.79$10.51B1.643.13 million shs2.78 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARZAralez Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ATCAtotech0.00%0.00%0.00%0.00%0.00%SCASavary Gold0.00%0.00%0.00%0.00%0.00%SGISilicon Graphics International0.00%-3.43%+4.15%+680.65%+680.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARZAralez PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATCAtotechN/AN/AN/AN/AN/AN/AN/AN/ASCASavary GoldN/AN/AN/AN/AN/AN/AN/AN/ASGISilicon Graphics International2.6765 of 5 stars3.40.01.70.00.62.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARZAralez Pharmaceuticals 0.00N/AN/AN/AATCAtotech 0.00N/AN/AN/ASCASavary Gold 0.00N/AN/AN/ASGISilicon Graphics International 2.83Moderate Buy$70.2016.03% UpsideCurrent Analyst Ratings BreakdownLatest SCA, ARZ, SGI, and ATC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025SGISilicon Graphics InternationalUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$81.00 ➝ $75.005/9/2025SGISilicon Graphics InternationalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$68.00 ➝ $77.004/11/2025SGISilicon Graphics InternationalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$70.00 ➝ $68.003/19/2025SGISilicon Graphics InternationalThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$57.003/13/2025SGISilicon Graphics InternationalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$76.00 ➝ $70.003/11/2025SGISilicon Graphics InternationalRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$62.00 ➝ $67.002/21/2025SGISilicon Graphics InternationalTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$72.00 ➝ $75.002/21/2025SGISilicon Graphics InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARZAralez PharmaceuticalsN/AN/AN/AN/AN/AN/AATCAtotech$1.50B2.95$1.15 per share19.72$4.24 per share5.36SCASavary GoldN/AN/AC$0.01 per share14.38C$0.05 per shareN/ASGISilicon Graphics International$4.93B2.13$3.53 per share17.14$3.22 per share18.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARZAralez PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AATCAtotech$7.50M$0.6137.23∞N/A8.14%20.32%5.25%N/ASCASavary GoldN/A-C$0.00N/A∞N/AN/AN/AN/AN/ASGISilicon Graphics International$368.10M$2.1628.0118.852.077.79%97.77%9.23%N/ALatest SCA, ARZ, SGI, and ATC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025N/ASGISilicon Graphics International$0.47$0.49+$0.02N/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARZAralez PharmaceuticalsN/AN/AN/AN/AN/AATCAtotechN/AN/AN/AN/AN/ASCASavary GoldN/AN/AN/AN/AN/ASGISilicon Graphics International$0.520.86%N/A24.07%1 YearsLatest SCA, ARZ, SGI, and ATC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/8/2025SGISilicon Graphics Internationalquarterly$0.150.99%5/22/20255/22/20256/5/20252/20/2025SGISilicon Graphics Internationalquarterly$0.150.9%3/6/20253/6/20253/20/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARZAralez PharmaceuticalsN/AN/AN/AATCAtotech1.891.901.45SCASavary GoldN/A10.0610.04SGISilicon Graphics International6.691.110.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARZAralez PharmaceuticalsN/AATCAtotech94.57%SCASavary GoldN/ASGISilicon Graphics International99.86%Insider OwnershipCompanyInsider OwnershipARZAralez PharmaceuticalsN/AATCAtotech49.90%SCASavary GoldN/ASGISilicon Graphics International3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARZAralez Pharmaceuticals4,50067.19 millionN/ANot OptionableATCAtotech4,033194.66 million97.53 millionNot OptionableSCASavary Gold1,228255.63 millionN/ANot OptionableSGISilicon Graphics International12,000173.65 million166.88 millionNot OptionableSCA, ARZ, SGI, and ATC HeadlinesRecent News About These CompaniesSomnigroup Announces Pricing of Secondary Offering of Common StockMay 12 at 5:57 PM | prnewswire.comSomnigroup Announces Launch of Secondary Offering of Common StockMay 12 at 6:42 AM | prnewswire.comSomnigroup International (SGI) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 8, 2025 | zacks.comSomnigroup International (SGI) Beats Q1 Earnings EstimatesMay 8, 2025 | zacks.comSomnigroup Announces Second Quarter Cash DividendMay 8, 2025 | prnewswire.comSomnigroup International Inc. Reports First Quarter ResultsMay 8, 2025 | prnewswire.comSomnigroup International Announces Multiple Mattress Firm Supplier ArrangementsMay 6, 2025 | prnewswire.comPurple Announces Significant Expansion of Commercial Relationship with SomnigroupMay 6, 2025 | prnewswire.comAhead of Somnigroup International (SGI) Q1 Earnings: Get Ready With Wall Street Estimates for Key MetricsMay 5, 2025 | zacks.comAnalysts Estimate Somnigroup International (SGI) to Report a Decline in Earnings: What to Look Out forMay 1, 2025 | zacks.comSomnigroup International Announces New Chief Human Resources OfficerApril 22, 2025 | prnewswire.comSomnigroup International Inc SGIMarch 9, 2025 | morningstar.comSGI Somnigroup International Inc.March 8, 2025 | seekingalpha.comMore Sleep, Less Rest: New Data Reveals America's Sleep DilemmaMarch 7, 2025 | prnewswire.comSomnigroup Announces New President of Mattress FirmMarch 5, 2025 | prnewswire.comSGI Global Welcomes New Chief Strategy OfficerFebruary 24, 2025 | tmcnet.comMattress Firm Launches FirmCare Powered by Extend to Boost Customer SatisfactionFebruary 24, 2025 | prnewswire.comSomnigroup International (SGI) Is a Great Choice for 'Trend' Investors, Here's WhyFebruary 20, 2025 | zacks.comSomnigroup International (SGI) Surpasses Q4 Earnings and Revenue EstimatesFebruary 20, 2025 | zacks.comTempur Sealy to change name to Somnigroup, ticker to ‘SGI’February 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesBroadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostBy Leo Miller | May 7, 2025View Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostApplied Digital: AI Data Center Hype or Real Value?By Jea Yu | April 21, 2025View Applied Digital: AI Data Center Hype or Real Value?3 Stocks to Buy Now for Tariff ImmunityBy Gabriel Osorio-Mazilli | April 23, 2025View 3 Stocks to Buy Now for Tariff ImmunityWhy Uber’s Stock Could Soar on AV Growth and Tariff ResilienceBy Jea Yu | April 16, 2025View Why Uber’s Stock Could Soar on AV Growth and Tariff ResilienceDisney: The Compelling Case for Buying Now Before They Scale UpBy Jea Yu | April 29, 2025View Disney: The Compelling Case for Buying Now Before They Scale UpSCA, ARZ, SGI, and ATC Company DescriptionsAralez Pharmaceuticals TSE:ARZAralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.Atotech NYSE:ATCAtotech Limited, a chemicals technology company, provides specialty electroplating and surface finishing solutions worldwide. The company operates through two segments, Electronics (EL) and General Metal Finishing (GMF). The EL segment manufactures and supplies chemistry, production equipment, software, and services to the electronics industry, which include printed circuit board manufacturers, package substrate makers, and semiconductor companies. Its products and technologies serve the principal electronics end-markets, including communication, computer, automotive, industrial, medical, aerospace, and military industries. The GMF segment provides chemistry, production technology, and services to the surface finishing industries in various areas of application. Its products and technologies serve the primary surface finishing end-markets comprising the automotive, consumer electronics, construction, sanitary, white goods, and oil and gas industries. The company also offers on-site support and training services. Atotech Limited was founded in 1851 and is headquartered in Berlin, Germany.Savary Gold CVE:SCAC$0.12 -0.01 (-4.17%) As of 05/2/2019Savary Gold Corp. engages in the exploration and evaluation of gold properties in West Africa. Its principal project is the Karankasso project that consists of five exploration licenses covering a total area of 688 square kilometers located in the Houndé Gold Belt in Burkina Faso. The company was formerly known as Savary Capital Corp. and changed its name to Savary Gold Corp. in September 2012. Savary Gold Corp. was incorporated in 2008 and is headquartered in Toronto, Canada.Silicon Graphics International NASDAQ:SGISilicon Graphics International Corp. (SGI) is engaged in providing solutions for compute, data analytics and data management. The Company develops, markets and sells a line of mid-range and high-end scale-out and scale-up servers, enterprise-class storage, differentiating software and designed-to-order solutions for data center deployments. The Company operates through the segments, including Product and Service. The Company's Product segment consists of compute and storage solutions, which include products from both HPC and HPDA segments. The Company's Product segment includes scale-out computing, scale-up computing, software and cloud/Web solutions. Its storage solutions include both hardware and software offerings for data storage and management. The Service segment consists of customer service support and professional services. SGI systems enable customers to access, analyze, transform, manage and visualize information in real and near real-time. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
